Topotecan Hydrochloride Articles
Merck Serono pulls European application for oral MS drug Movectro; Sun withdraws topotecan
18 February 2011
UK’s NICE backs GSK’s Hycamtin for cervical cancer and Lilly’s Efient for preventing blood clots
28 October 2009
SCLC drug market wil more than double to $648M in 2017
14 April 2009
Treatment begins in Ph III karenitecin trial
18 February 2008
GSK's Hycamtin gets opinion from EMEA for SCLC
11 February 2008
GSK's Hycamtin gets FDA OK
22 October 2007
Hycamtin gets EU OK for cervical cancer
11 December 2006
GSK's Tykerb under EMEA review
16 October 2006
Expanded US label for GSK's Hycamtin
26 June 2006
FDA accepts sNDA on GSK's Hycamtin
27 February 2006
EC OKs GSK's Hycamtin for relapsed SCLC
6 February 2006
GSK's Hycamtin gets positive CHMP feedback
5 December 2005
NY claims of Rx overcharging could lead to industry-wide probe
24 February 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
UK launch for Schering-Plough's Caelyx
31 October 2000
Coulter reacquires ex-USA Bexxar rights
26 April 2000
Schering-Plough files for EMEA Caelyx OK - updated
3 February 2000
SB sales increase 11% boosted by Avandia
21 July 1999
US advisory committee OKs Alza's Doxil
10 June 1999
Currency impact lifts SmithKline Beecham
20 April 1999
Enzon applies to test Prothecan in USA
6 April 1999
SB warned by FDA over US plant
3 February 1999
SB To Jointly Commercialize Coulter's Cancer Therapy
8 December 1998
Solid Third Quarter At SB Thanks To New Products
20 October 1998
Hycamtin Approved For SCLC
14 September 1998
Currency And Flu Factors Hold Back SB Results
22 July 1998
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
Cancer Market Growth Forecasts To 2010
15 June 1998
SB's Hycamtin Supported For SCLC
4 June 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
SB's 1st-Quarter Impacted Again By Strong Sterling
22 April 1998
Hycamtin Potential In Multiple Myeloma?
4 March 1998
Currency Hits SmithKline Beecham Sales And Profits
17 February 1998
GW-SB Merger Will Create R&D Superpower
5 February 1998
SB's Hycamtin: Expanded Indications?
11 December 1997
New Data With SB's Hycamtin In SCLC
22 August 1997
Strong Sterling Impacts SmithKline Beecham
23 July 1997
Upbeat UK Companies At Goldman Sachs Conference
17 June 1997
Hycamtin Of Value In NSCLC
30 May 1997
B-MS And RTI To Develop Camptothecin Analogs
19 May 1997
UK Launch Of SmithKline Beecham's Hycamtin
17 February 1997
Record Number Of New Chemical Entities In 1996
20 January 1997
SmithKline Beecham's Hycamtin Receives EU Approval
25 November 1996
SB's Hycamtin Approved In UK
18 November 1996
SmithKline Beecham: A Leader In Spanish Market
19 August 1996
FDA Appro For Pharmacia & Upjohn's Camptosar
24 June 1996
First Approval Of SB's Hycamtin
3 June 1996
SB's Hycamtin Backed By US Committee
29 April 1996
SB Trading Profit Up 19% On New Prods
26 February 1996
Topotecan As 1st-Line Ovarian Cancer Drug
13 November 1995
SmithKline Beecham Unveils Power Pipeline
9 October 1995
Highlights Of SmithKline's R&D Portfolio
2 January 1995
SmithKline Beecham On Adapting To Change
10 October 1994
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
Showing 1-65 of 65 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
